Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide
The durability and capacity to boost protein expression of circular RNA makes it a promising candidate for next-generation vaccines and gene therapies.
Paolo Martini leads the biotech company’s rare disease research program with the hope of developing the very first treatments for genetic metabolic disorders.
A new porcine model for the rare neurological disorder CLN3 Batten disease more faithfully recreates human symptoms and could accelerate drug development.